Octreotide as primary therapy for acromegaly.

Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D and 6 more

Show all authors

Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL

The Journal of clinical endocrinology and metabolism1 Sept 1998Cited by 150 (Europe PMC)

PMID9745397DOI10.1210/jcem.83.9.5109PepBankPUB-09745397

Source link PubMedAsk about this study

Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanNon-randomized trialEfficacy outcome
In secondary-treated acromegaly, GH fell from 30.2 +/- 7.6 to 5.6 +/- 1.1 micrograms/L after 3 months and remained suppressed with octreotide.
In plain wordsIn secondary-treated acromegaly, GH fell after octreotide compared with baseline and remained suppressed.
Peptide
Octreotide
Outcome
DecreaseGH during secondary therapy
Study
n = 81
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Average 635 micrograms daily · subcutaneousAs given in this study (human).
Measurements
GH concentration
30.2 micrograms/L
secondary therapy group, baseline
GH concentration
5.6 micrograms/L
secondary therapy group, after 3 months
Source sentences
Summary
In the patients receiving secondary treatment, mean GH fell from 30.2 +/- 7.6 to 5.6 +/- 1.1 micrograms/L after 3 months and remained suppressed for the remainder of the study (average dose, 635 micrograms daily).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539705
02HumanNon-randomized trialEfficacy outcome
In secondary-treated acromegaly, IGF-I fell from 4.7 +/- 0.4 to 2.2 +/- 0.3 x 10(3) U/L after 3 months of open-label octreotide.
In plain wordsIn secondary-treated acromegaly, IGF-I fell after open-label octreotide compared with baseline.
Peptide
Octreotide
Outcome
DecreaseIGF-I during secondary therapy
Study
n = 81
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
IGF-I concentration
4.7 x 10(3) U/L
secondary therapy group, baseline
IGF-I concentration
2.2 x 10(3) U/L
secondary therapy group, after 3 months of open label treatment
Source sentences
Summary
Mean IGF-I concentrations fell from 5.2 +/- 0.5 x 10(3) U/L (primary treatment group) and 4.7 +/- 0.4 x 10(3) U/L (secondary treatment group) to a mean of 2.2 +/- 0.3 x 10(3) U/L in both groups after 3 months of open label treatment and remained suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539707
03HumanNon-randomized trialEfficacy outcome
In secondary-treated acromegaly, 62% had normal IGF-I during at least half of octreotide study visits.
In plain wordsIn secondary-treated acromegaly, 62% had normal IGF-I during at least half of octreotide study visits.
Peptide
Octreotide
Outcome
Not applicableNormal IGF-I during secondary therapy
Study
n = 81
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with IGF-I in normal range during at least half of study visits
62%
secondary treatment group
Source sentences
Summary
IGF-I was reduced into the normal range during at least half of the study visits in 68% of the primary treatment group and in 62% of the secondary treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539709
04HumanNon-randomized trialEfficacy outcome
In secondary-treated acromegaly, headache, perspiration, fatigue, and joint pain improved in 62-88% during octreotide therapy.
In plain wordsIn secondary-treated acromegaly, reported symptoms improved during octreotide therapy compared with baseline.
Peptide
Octreotide
Outcome
DecreaseSymptoms during secondary therapy
Study
n = 81
Comparator
Baseline
Outcome group
Acromegaly Symptoms · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Baseline headache
62%
secondary group
Baseline perspiration
58%
secondary group
Baseline fatigue
78%
secondary group
Baseline joint pain
60%
secondary group
Patients with improvement in headache, perspiration, fatigue and joint pain
62 to 88 % of patients
secondary group
Source sentences
Summary
Similarly, these acromegaly-related symptoms were reported by 62%, 58%, 78%, and 60% of patients in the secondary therapy group, and improvement was noted in 62-88%.
2 context sentences(design, population, supporting numbers)
Summary · context
Symptoms of headache, increased perspiration, fatigue, and joint pain were reported at baseline by 46%, 73%, 69%, and 85%, respectively, of patients in the primary therapy group and improved during 3 yr of octreotide treatment in 50-100%.
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539713
05HumanNon-randomized trialEfficacy outcome
In primary-treated acromegaly, mean GH fell from 32.7 +/- 5.2 to 6.0 +/- 1.7 micrograms/L 2 h after octreotide injection and remained suppressed for a mean 24 months.
In plain wordsIn primary-treated acromegaly, GH fell after octreotide compared with baseline and remained suppressed.
Peptide
Octreotide
Outcome
DecreaseGH during primary therapy
Study
n = 26
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
GH concentration
32.7 micrograms/L
primary therapy group, baseline (SD or SE 5.2 as written)
GH concentration
6 micrograms/L
primary therapy group, 2 h after octreotide injection
Mean period of GH suppression
24 months
primary therapy group
Range of GH suppression period
3 to 60 months
primary therapy group
Source sentences
Summary
During long term open label treatment, mean GH fell from 32.7 +/- 5.2 to 6.0 +/- 1.7 micrograms/L 2 h after octreotide injection in the primary therapy group and remained suppressed for a mean period of 24 months (range, 3-60 months).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539703
06HumanNon-randomized trialOther
In primary-treated acromegaly, the mean final daily octreotide dose was 777 micrograms.
In plain wordsIn primary-treated acromegaly, the mean final daily octreotide dose was 777 micrograms.
Peptide
Octreotide
Outcome
Not applicableFinal daily dose in primary therapy
Study
n = 26
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
mean final daily dose 777 micrograms · subcutaneousAs given in this study (human).
Measurements
Mean final daily dose
777 micrograms
primary therapy group
Source sentences
Summary
The mean final daily dose was 777 micrograms.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539704
07HumanNon-randomized trialEfficacy outcome
In primary-treated acromegaly, IGF-I fell from 5.2 +/- 0.5 to 2.2 +/- 0.3 x 10(3) U/L after 3 months of open-label octreotide.
In plain wordsIn primary-treated acromegaly, IGF-I fell after open-label octreotide compared with baseline.
Peptide
Octreotide
Outcome
DecreaseIGF-I during primary therapy
Study
n = 26
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
IGF-I concentration
5.2 x 10(3) U/L
primary therapy group, baseline
IGF-I concentration
2.2 x 10(3) U/L
primary therapy group, after 3 months of open label treatment
Source sentences
Summary
Mean IGF-I concentrations fell from 5.2 +/- 0.5 x 10(3) U/L (primary treatment group) and 4.7 +/- 0.4 x 10(3) U/L (secondary treatment group) to a mean of 2.2 +/- 0.3 x 10(3) U/L in both groups after 3 months of open label treatment and remained suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539706
08HumanNon-randomized trialEfficacy outcome
In primary-treated acromegaly, 68% had normal IGF-I during at least half of octreotide study visits.
In plain wordsIn primary-treated acromegaly, 68% had normal IGF-I during at least half of octreotide study visits.
Peptide
Octreotide
Outcome
Not applicableNormal IGF-I during primary therapy
Study
n = 26
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with IGF-I in normal range during at least half of study visits
68%
primary treatment group
Source sentences
Summary
IGF-I was reduced into the normal range during at least half of the study visits in 68% of the primary treatment group and in 62% of the secondary treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539708
09HumanNon-randomized trialEfficacy outcome
In primary-treated acromegaly, headache, perspiration, fatigue, and joint pain improved in 50-100% during octreotide therapy.
In plain wordsIn primary-treated acromegaly, reported symptoms improved during octreotide therapy compared with baseline.
Peptide
Octreotide
Outcome
DecreaseSymptoms during primary therapy
Study
n = 26
Comparator
Baseline
Outcome group
Acromegaly Symptoms · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 yrAs given in this study (human).
Measurements
Baseline headache
46%
primary group
Baseline perspiration
73%
primary group
Baseline fatigue
69%
primary group
Baseline joint pain
85%
primary group
Patients with improvement in headache, perspiration, fatigue and joint pain
50 to 100 % of patients
primary group, during 3 yr of octreotide
Source sentences
Summary
Symptoms of headache, increased perspiration, fatigue, and joint pain were reported at baseline by 46%, 73%, 69%, and 85%, respectively, of patients in the primary therapy group and improved during 3 yr of octreotide treatment in 50-100%.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539712
10HumanNon-randomized trialEfficacy outcome
In acromegaly patients given octreotide as primary therapy, tumor shrinkage was observed in 6 of 13 patients with MRI scans before and after 6 months of treatment, with volume reduction greater than 25% in only 3.
In plain wordsIn primary-treated acromegaly, tumors shrank in 6 of 13 patients after octreotide compared with baseline.
Peptide
Octreotide
Outcome
DecreaseTumor shrinkage
Study
n = 13
Comparator
Baseline
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with tumor shrinkage
6 patients
primary group, 13 patients with MRI scans before and after 6 months
Patients with tumor volume reduction greater than 25%
3 patients
primary group, 13 patients with MRI scans
Source sentences
Summary
Tumor shrinkage was observed in 6 of 13 patients, with reduction in tumor volume greater than 25% in only 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Pituitary magnetic resonance imaging scans were available in 13 of 26 patients in the primary treatment group before and after 6 months of octreotide treatment.
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539714
11HumanNon-randomized trialEfficacy outcome
In acromegaly, the abstract gives conflicting normal IGF-I counts of 4 and 5 among the same 7 octreotide patients with tumor shrinkage below 10%.
In plain wordsIn acromegaly, the abstract reports conflicting counts, 4 and 5 of 7 octreotide patients, for normal IGF-I with little tumor shrinkage.
Peptide
Octreotide
Outcome
Not applicableNormal IGF-I with little tumor shrinkage, conflicting counts
Study
n = 7
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with IGF-I reduced into the normal range (first sentence)
4 patients
primary group, 7 patients with tumor shrinkage below 10%; conflicts with the repeated sentence
Patients with IGF-I reduced into the normal range (repeated sentence)
5 patients
primary group, 7 patients with tumor shrinkage below 10%; conflicts with the first sentence
Source sentences
Summary
Of the 7 remaining patients in whom tumor shrinkage was less than 10%, IGF-I was reduced into the normal range in 4 patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Of the 7 remaining patients in whom tumor shrinkage was less than 10%, IGF-I was reduced into the normal range in 5 patients.
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539716
12HumanNon-randomized trialEfficacy outcome
In acromegaly, IGF-I normalized with octreotide in 4 of 6 patients with documented tumor shrinkage.
In plain wordsIn acromegaly, IGF-I normalized with octreotide in 4 of 6 patients with tumor shrinkage.
Peptide
Octreotide
Outcome
Not applicableNormal IGF-I among patients with tumor shrinkage
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with IGF-I reduced into the normal range
4 patients
primary group, 6 patients with documented tumor shrinkage
Source sentences
Summary
Of 6 patients with documented tumor shrinkage, IGF-I was reduced into the normal range in 4 patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539715
13HumanObservational studyEfficacy outcome
In acromegaly, integrated GH after 3 and 6 months of octreotide was equivalent in primary and secondary treatment groups.
In plain wordsIn acromegaly, GH after octreotide was equivalent in primary and secondary treatment groups.
Peptide
Octreotide
Outcome
No significant changeIntegrated GH at three and six months
Study
n: not reported in source
Comparator
Secondary treatment group
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 or 250 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
In the second phase of the study, in which patients were randomized to either 100 or 250 micrograms octreotide, three times daily, mean integrated GH and IGF-I concentrations after 3 and 6 months were equivalent in the primary and secondary treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539701
14HumanObservational studyEfficacy outcome
In acromegaly, IGF-I after 3 and 6 months of octreotide was equivalent in primary and secondary treatment groups.
In plain wordsIn acromegaly, IGF-I after octreotide was equivalent in primary and secondary treatment groups.
Peptide
Octreotide
Outcome
No significant changeIGF-I at three and six months
Study
n: not reported in source
Comparator
Secondary treatment group
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 or 250 micrograms three times daily · subcutaneousAs given in this study (human).
Source sentences
Summary
In the second phase of the study, in which patients were randomized to either 100 or 250 micrograms octreotide, three times daily, mean integrated GH and IGF-I concentrations after 3 and 6 months were equivalent in the primary and secondary treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539702
15HumanObservational studyEfficacy outcome
In acromegaly, octreotide responder proportions were 70% in primary versus 61% in secondary therapy, without a significant difference.
In plain wordsIn acromegaly, octreotide response was 70% in primary versus 61% in secondary therapy, without a significant difference.
Peptide
Octreotide
Outcome
IncreaseGH responder proportion
Study
n: not reported in source
Comparator
Secondary treatment group
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Responder percentage
70%
primary treatment group
Responder percentage
61%
secondary treatment group
Source sentences
Summary
There was no significant difference in the percentage of responders in the primary and secondary treatment groups (70% vs. 61%), nor was there a statistical difference in the mean GH concentrations between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients whose GH levels fell to at least 2 SD below the baseline mean GH were considered responders.
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539710
16HumanObservational studyEfficacy outcome
In acromegaly, mean GH during octreotide therapy did not differ statistically between primary and secondary treatment groups.
In plain wordsIn acromegaly, mean GH during octreotide therapy did not differ statistically between primary and secondary treatment groups.
Peptide
Octreotide
Outcome
No significant changeMean GH comparison
Study
n: not reported in source
Comparator
Secondary treatment group
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
There was no significant difference in the percentage of responders in the primary and secondary treatment groups (70% vs. 61%), nor was there a statistical difference in the mean GH concentrations between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539711
17HumanObservational studyMechanism
In acromegaly during octreotide therapy, tumor shrinkage did not correlate with percentage IGF-I reduction.
In plain wordsIn acromegaly during octreotide therapy, tumor shrinkage was not linked to percentage IGF-I reduction.
Peptide
Octreotide
Outcome
No significant changeTumor shrinkage correlation with IGF-I reduction
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The degree of tumor shrinkage did not correlate with the percent reduction in IGF-I or GH.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539717
18HumanObservational studyMechanism
In acromegaly during octreotide therapy, tumor shrinkage did not correlate with percentage GH reduction.
In plain wordsIn acromegaly during octreotide therapy, tumor shrinkage was not linked to percentage GH reduction.
Peptide
Octreotide
Outcome
No significant changeTumor shrinkage correlation with GH reduction
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The degree of tumor shrinkage did not correlate with the percent reduction in IGF-I or GH.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly were compared with those in 81 patients with acromegaly who received octreotide as secondary or adjunctive therapy after previous surgery and/or pituitary radiation.
Report a problemFND-0974539718

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.